ozekibart (INBRX-109) Phase 1 Trial
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of ozekibart (INBRX-109) in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
ClinicalTrials.gov
Key Eligibility Criteria:
C3 Cohort:
+ Locally advanced, metastatic, unresectable, recurrent or refractory Ewing sarcoma
+ Age ≥12 to <85 years
+ 1-2 prior lines of chemotherapy
+ Prior irinotecan and temozolomide allowed
+ No chronic or acute liver disease
C4 Cohort:
+ Locally advanced or metastatic, unresectable colorectal carcinoma
+ 2-3 prior lines of systemic therapy
+ No chronic or acute liver disease